The Annual General Body Meeting of the Society of Rgcb was held yesterday (12th Nov 2021) at New Delhi under the presidentship of Dr. Jitendra Singh, Hon. MoS (IC) S&T. Dr Singh, said RGCB will be developed as a hub for research and testing of multiple vaccines such as cancer vaccine and those for infectious diseases, including Covid-19. "This will bring huge recognition for RGCB in the specific area of vaccine research and development." The minister lauded the RGCB's model of supporting both innovative research and Biotechnology incubation facility. RGCB Director Prof Chandrabhas Narayana explained the new facilities that will be created in the new campus . He said the centre will have cutting edge technologies, therapies, clinical trials for cancer vaccines, and immune therapeutics. It will also have facilities for therapies such as stem cell replacement, Gene therapy, molecular tumor targeting and Imaging. Those who attended meeting include: Dr Rajesh S Gokhale, Secretary, Department of Biotechnology, Government of India, Shri Vishvajit Sahay, Additional Secretary & Financial Advisor, DBT, Shri Sunil Kumar, Joint Secretary, DBT and Dr. Sundeep Sarin, Scientific Coordinator for RGCB at DBT. Dr Shekhar C Mande, Secretary, Department of Scientific and Industrial Research & DG-CSIR Government of India also attended the meeting. Department of Biotechnology, India


Rajiv Gandhi Centre for Biotechnology (RGCB),
Thycaud Post, Poojappura,
Thiruvananthapuram - 695 014, Kerala, India
+91-471-2529400 | 2347975 | 2348753